PA

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Seiler T et al. – High response rates and durable remissions have been seen with both 90Y–ibritumomab tiuxetan and 131I–tositumomab. However, refractoriness to immunochemotherapy still remains a problem, especially in relapsed disease. Several novel targeted agents show encouraging activity in follicular lymphoma. This review will focus on current treatment strategies in this disease.


   

Today in Hematology/Oncology...keeping you current

Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement
Annals of Internal Medicine, 11/17/09

Approach to Thrombocytopenia in Older Adults
Geriatrics & Aging, 11/10/09

Update on oral lichen planus
Expert Review of Dermatology, 10/14/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address